ribosomal protein L26Genealiases: DBA11 · L26 · uL24
Q-omics provides the consensus-scored RPL26 profile across patient tissues and cancer cell-line models. RPL26 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL26 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPL26 RNA expression shows 18,483 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RPL26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26 survival associations across molecular data types. RPL26 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26 RNA expression–survival associations across cancer types. High RPL26 expression shows unfavorable associations in ACC, KICH, LIHC and LUAD, but favorable associations in BRCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL26 RNA expression.
This table summarizes RPL26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26 shows lower tumor expression in BRCA, UCEC and KICH and higher tumor expression in KIRC, CHOL and KIRP. The KIRC box plot shows higher RPL26 RNA expression in tumor versus normal tissue (log2 FC = +0.623, t-test p < 0.001).
This table shows molecular features associated with RPL26 in patient tissues and cancer cell lines. In patient samples, RPL26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
